From Schizophrenia Genetics to Disease Biology: Harnessing New Concepts and Technologies-Journal of Psychiatry and Brain Science-CSCIED科技核心评价数据库-手机版

From Schizophrenia Genetics to Disease Biology: Harnessing New Concepts and Technologies

From Schizophrenia Genetics to Disease Biology: Harnessing New Concepts and Technologies

ES评分 0 浏览量：689 下载量：0

DOI	10.20900/jpbs.20190014
刊名	Journal of Psychiatry and Brain Science JPBS
年，卷(期)	2019, 4(5)
作者	Jubao Duan*,Alan R. Sanders,Pablo V. Gejman,
作者单位	1 Center for Psychiatric Genetics, NorthShore University HealthSystem, Evanston, IL 60201, USA; 2 Department of Psychiatry and Behavioral Neurosciences, The University of Chicago, Chicago, IL 60637, USA
Abstract	Schizophrenia (SZ) is a severe mental disorder afflicting around 1% of the population. It is highly heritable but with complex genetics. Recent research has unraveled a plethora of risk loci for SZ. Accordingly, our conceptual understanding of SZ genetics has been rapidly evolving, from oligogenic models towards polygenic or even omnigenic models. A pressing challenge to the field, however, is the translation of the many genetic findings of SZ into disease biology insights leading to more effective treatments. Bridging this gap requires the integration of genetic findings and functional genomics using appropriate cellular models. Harnessing new technologies, such as the development of human induced pluripotent stem cells (hiPSC) and the CRISPR/Cas-based genome/epigenome editing approach are expected to change our understanding of SZ disease biology to a fundamentally higher level. Here, we discuss some new developments.
KeyWord	schizophrenia; genetics; genome-wide association study; functional genomics; epigenomics; chromatin modification; model organism; human induced pluripotent stem cells (hiPSCs); genome editing
基金项目
页码	-

参考文献
相关文献

1.Owen MJ, Sawa A, Mortensen PB. Schizophrenia. Lancet. 2016;388(10039):86-97.

2.Carlsson A, Lindqvist M. Effect of Chlorpromazine or Haloperidol on Formation of 3methoxytyramine and Normetanephrine in Mouse Brain. Acta Pharmacol Toxicol. 1963;20:140-4.

3.Shi J, Levinson DF, Duan J, Sanders AR, Zheng Y, Pe’er I, et al. Common variants on chromosome 6p22.1 are associated with schizophrenia. Nature. 2009;460(7256):753-7.

4.Purcell SM, Wray NR, Stone JL, Visscher PM, O’Donovan MC, Sullivan PF, et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature. 2009;460(7256):748-52.

5.Stefansson H, Ophoff RA, Steinberg S, Andreassen OA, Cichon S, Rujescu D, et al. Common variants conferring risk of schizophrenia. Nature. 2009;460(7256):744-7.

6.Consortium SPG-WASG. Genome-wide association study identifies five new schizophrenia loci. Nat Genet. 2011;43(10):969-76.

7.Ripke S. Psychiatric genomics consortium quadruples schizophrenia GWAS sample size to 35,000 cases and 47,000 controls. Abstract presented at ASHG2013. American Society of Human Genetics 63rdAnnual Meeting; 2013 Oct 22–26; Boston, MA, USA.

8.Schizophrenia Working Group of the Psychiatric Genomics Consortium; Ripke S, Neale BM, Corvin A, Walters JTR, Farh K-H, et al. Biological insights from 108 schizophrenia-associated genetic loci. Nature. 2014;511(7510):421-7.

9.Boyle EA, Li YI, Pritchard JK. An Expanded View of Complex Traits: From Polygenic to Omnigenic. Cell. 2017;169(7):1177-86.

10.Bassett AS, Scherer SW, Brzustowicz LM. Copy Number Variations in Schizophrenia: Critical Review and New Perspectives on Concepts of Genetics and Disease. Am J Psychiatry. 2010;167(8):899-914. doi: 10.1176/appi.ajp.2009.09071016

11.Levinson DF, Duan J, Oh S, Wang K, Sanders AR, Shi J, et al. Copy number variants in schizophrenia: confirmation of five previous findings and new evidence for 3q29 microdeletions and VIPR2 duplications. Am J Psychiatry. 2011;168(3):302-16.

12.Szatkiewicz JP, O’Dushlaine C, Chen G, Chambert K, Moran JL, Neale BM, et al. Copy number variation in schizophrenia in Sweden. Mol Psychiatry. 2014;19(7):762-73. doi: 10.1038/mp.2014.40

13.Marshall CR, Howrigan DP, Merico D, Thiruvahindrapuram B, Wu W, Greer DS, et al. Contribution of copy number variants to schizophrenia from a genome-wide study of 41,321 subjects. Nat Genet. 2017;49(1):27-35.

14.Canela-Xandri O, Rawlik K, Tenesa A. An atlas of genetic associations in UK Biobank. Nat Genet. 2018;50(11):1593-9.

15.Ward J, Tunbridge EM, Sandor C, Lyall LM, Ferguson A, Strawbridge RJ, et al. The genomic basis of mood instability: identification of 46 loci in 363,705 UK Biobank participants, genetic correlation with psychiatric disorders, and association with gene expression and function. Mol Psychiatry. 2019. doi: 10.1038/s41380-019-0439-8

16.Gottesman, II, Shields J. A polygenic theory of schizophrenia. Proc Natl Acad Sci U S A. 1967;58(1):199-205.

17.O’Donovan MC, Owen MJ. Candidate-gene association studies of schizophrenia. Am J Hum Genet. 1999;65(3):587-92.

18.Sullivan PF. How Good Were Candidate Gene Guesses in Schizophrenia Genetics? Biol Psychiatry. 2017;82(10):696-7.

19.Johnson EC, Border R, Melroy-Greif WE, de Leeuw CA, Ehringer MA, Keller MC. No Evidence That Schizophrenia Candidate Genes Are More Associated With Schizophrenia Than Noncandidate Genes. Biol Psychiatry. 2017;82(10):702-8.

20.O’Donovan MC, Owen MJ. The implications of the shared genetics of psychiatric disorders. Nat Med. 2016;22(11):1214-9.

21.Gershon ES. Bipolar illness and schizophrenia as oligogenic diseases: implications for the future. Biol Psychiatry. 2000;47(3):240-4.

22.Riley B. Linkage studies of schizophrenia. Neurotoxic Res. 2004;6(1):17-34.

23.Sklar P. Linkage Analysis In Psychiatric Disorders: The Emerging Picture. Annu Rev Genomics Hum Genet. 2002;3:371-413.

24.Norton N, Williams HJ, Owen MJ. An update on the genetics of schizophrenia. Curr Opin Psychiatry. 2006;19(2):158-64.

25.Kendler KS. A joint history of the nature of genetic variation and the nature of schizophrenia. Mol Psychiatry. 2015;20(1):77-83.

26.Badner JA, Gershon ES. Meta-analysis of whole-genome linkage scans of bipolar disorder and schizophrenia. Mol Psychiatry. 2002;7(4):405-11.

27.Lewis CM, Levinson DF, Wise LH, DeLisi LE, Straub RE, Hovatta I, et al. Genome scan meta-analysis of schizophrenia and bipolar disorder, part II: Schizophrenia. Am J Hum Genet. 2003;73(1):34-48.

28.Suarez BK, Duan J, Sanders AR, Hinrichs AL, Jin CH, Hou C, et al. Genomewide linkage scan of 409 European-ancestry and African American families with schizophrenia: suggestive evidence of linkage at 8p23.3-p21.2 and 11p13.1-q14.1 in the combined sample. Am J Hum Genet. 2006;78(2):315-33.

29.Sanders AR, Duan J, Levinson DF, Shi J, He D, Hou C, et al. No significant association of 14 candidate genes with schizophrenia in a large European ancestry sample: implications for psychiatric genetics. Am J Psychiatry. 2008;165(4):497-506.

30.Pardinas AF, Holmans P, Pocklington AJ, Escott-Price V, Ripke S, Carrera N, et al. Common schizophrenia alleles are enriched in mutation-intolerant genes and in regions under strong background selection. Nat Genet. 2018;50(3):381-9.

31.Martin AR, Daly MJ, Robinson EB, Hyman SE, Neale BM. Predicting Polygenic Risk of Psychiatric Disorders. Biol Psychiatry. 2019;86(2):97-109.

32.Brainstorm C, Anttila V, Bulik-Sullivan B, Finucane HK, Walters RK, Bras J, et al. Analysis of shared heritability in common disorders of the brain. Science. 2018;360(6395). doi: 10.1126/science.aap8757

33.Duncan LE, Shen H, Ballon JS, Hardy KV, Noordsy DL, Levinson DF. Genetic Correlation Profile of Schizophrenia Mirrors Epidemiological Results and Suggests Link Between Polygenic and Rare Variant (22q11.2) Cases of Schizophrenia. Schizophr Bull. 2018;44(6):1350-61.

34.Bipolar D, Schizophrenia Working Group of the Psychiatric Genomics Consortium. Electronic address drve, Bipolar D, Schizophrenia Working Group of the Psychiatric Genomics C. Genomic Dissection of Bipolar Disorder and Schizophrenia, Including 28 Subphenotypes. Cell. 2018;173(7):1705-15 e16.

35.Cardno AG, Owen MJ. Genetic relationships between schizophrenia, bipolar disorder, and schizoaffective disorder. Schizophr Bull. 2014;40(3):504-15.

36.Murphy KC, Jones LA, Owen MJ. High rates of schizophrenia in adults with velo-cardio-facial syndrome. Arch Gen Psychiatry. 1999;56(10):940-5.

37.Singh T, Walters JTR, Johnstone M, Curtis D, Suvisaari J, Torniainen M, et al. The contribution of rare variants to risk of schizophrenia in individuals with and without intellectual disability. Nat Genet. 2017;49(8):1167-73.

38.Thompson EA. Correlations between relatives: From Mendelian theory to complete genome sequence. Genet Epidemiol. 2019;43(5):577-91.

39.Wainschtein P, Jain DP, Yengo L, Zheng Z, Group. TOPMed Anthropometry Working Group, Trans-Omics for Precision Medicine Consortium, et al. Recovery of trait heritability from whole genome sequence data. BioRxiv
[Preprint]. 2019. doi: 10.1101/588020

40.Dhindsa RS, Copeland BR, Mustoe AM, Goldstein DB. Natural selection shapes codon usage in the human genome. BioRxiv
[Preprint]. 2019. doi: 10.1101/688051

41.Duan J, Wainwright MS, Comeron JM, Saitou N, Sanders AR, Gelernter J, et al. Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor. Hum Mol Genet. 2003;12(3):205-16.

42.Duan J, Antezana MA. Mammalian mutation pressure, synonymous codon choice, and mRNA degradation. J Mol Evol. 2003;57(6):694-701.

43.Duan J, Shi J, Ge X, Dolken L, Moy W, He D, et al. Genome-wide survey of interindividual differences of RNA stability in human lymphoblastoid cell lines. Sci Rep. 2013;3:1318.

44.Tansey KE, Rees E, Linden DE, Ripke S, Chambert KD, Moran JL, et al. Common alleles contribute to schizophrenia in CNV carriers. Mol Psychiatry. 2016;21(8):1085-9.

45.Bergen SE, Ploner A, Howrigan D, Group CNVA, the Schizophrenia Working Group of the Psychiatric Genomics C, O’Donovan MC, et al. Joint Contributions of Rare Copy Number Variants and Common SNPs to Risk for Schizophrenia. Am J Psychiatry. 2019;176(1):29-35.

46.Heath RG, Krupp IM. Schizophrenia as an immunologic disorder. I. Demonstration of antibrain globulins by fluorescent antibody techniques. Arch Gen Psychiatry. 1967;16(1):1-9.

47.Eaton WW, Byrne M, Ewald H, Mors O, Chen CY, Agerbo E, et al. Association of schizophrenia and autoimmune diseases: linkage of Danish national registers. Am J Psychiatry. 2006;163(3):521-8.

48.Hindorff LA, Sethupathy P, Junkins HA, Ramos EM, Mehta JP, Collins FS, et al. Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc Natl Acad Sci U S A. 2009;106(23):9362-7.

49.Girgis RR, Kumar SS, Brown AS. The cytokine model of schizophrenia: emerging therapeutic strategies. Biol Psychiatry. 2014;75(4):292-9.

50.Gierut JJ, Wood LB, Lau KS, Lin YJ, Genetti C, Samatar AA, et al. Network-level effects of kinase inhibitors modulate TNF-alpha-induced apoptosis in the intestinal epithelium. Sci Signal. 2015;8(407):ra129.

51.Duan J, Goring HHH, Sanders AR, Moy W, Freda J, Drigalenko EI, et al. Transcriptomic signatures of schizophrenia revealed by dopamine perturbation in an ex vivo model. Transl Psychiatry. 2018;8(1):158.

52.Sanders AR, Drigalenko EI, Duan J, Moy W, Freda J, Goring HHH, et al. Transcriptome sequencing study implicates immune-related genes differentially expressed in schizophrenia: new data and a meta-analysis. Transl Psychiatry. 2017;7(4):e1093.

53.Sanders AR, Goring HH, Duan J, Drigalenko EI, Moy W, Freda J, et al. Transcriptome study of differential expression in schizophrenia. Hum Mol Genet. 2013;22(24):5001-14. doi: 10.1093/hmg/ddt350

54.Sekar A, Bialas AR, de Rivera H, Davis A, Hammond TR, Kamitaki N, et al. Schizophrenia risk from complex variation of complement component 4. Nature. 2016;530(7589):177-83.

55.Petanjek Z, Judas M, Simic G, Rasin MR, Uylings HB, Rakic P, et al. Extraordinary neoteny of synaptic spines in the human prefrontal cortex. Proc Natl Acad Sci U S A. 2011;108(32):13281-6.

56.Thomas MS, Knowland VC, Karmiloff-Smith A. Mechanisms of developmental regression in autism and the broader phenotype: a neural network modeling approach. Psychol Rev. 2011;118(4):637-54.

57.Sellgren CM, Gracias J, Watmuff B, Biag JD, Thanos JM, Whittredge PB, et al. Increased synapse elimination by microglia in schizophrenia patient-derived models of synaptic pruning. Nat Neurosci. 2019;22(3):374-85.

58.Butler IRR, Kozlova A, Zhang H, Zhang S, Streit M, Sanders AR, et al. The Genetic Relevance of Human Induced Pluripotent Stem Cell-Derived Microglia to Alzheimer’s Disease and Major Neuropsychiatric Disorders. Mol Neuropsychiatry. 2019. doi: 10.1159/000501935

59.Muller N, Myint AM, Krause D, Weidinger E, Schwarz MJ. Anti-inflammatory treatment in schizophrenia. Prog Neuro-Psychopharmacol Biol Psychiatry. 2013;42:146-53.

60.Muller N, Myint AM, Schwarz MJ. Immunological treatment options for schizophrenia. Curr Pharm Biotechnol. 2012;13(8):1606-13.

61.Bialas AR, Presumey J, Das A, van der Poel CE, Lapchak PH, Mesin L, et al. Microglia-dependent synapse loss in type I interferon-mediated lupus. Nature. 2017;546(7659):539-43.

62.Creese I, Burt DR, Snyder SH. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science. 1976;192(4238):481-3.

63.Seeman P, Lee T. Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science. 1975;188(4194):1217-9.

64.Lieberman JA, Kane JM, Alvir J. Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology. 1987;91(4):415-33.

65.Snyder SH. The dopamine hypothesis of schizophrenia: focus on the dopamine receptor. Am J Psychiatry. 1976;133(2):197-202.

66.Snyder SH. Proceedings: Drugs, neurotransmitters, and psychosis. Psychopharmacol Bull. 1974;10(4):4-5.

67.Seeman P. Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse. 1987;1(2):133-52.

68.Howes OD, Kambeitz J, Kim E, Stahl D, Slifstein M, Abi-Dargham A, et al. The nature of dopamine dysfunction in schizophrenia and what this means for treatment. Arch Gen Psychiatry. 2012;69(8):776-86.

69.Mita T, Hanada S, Nishino N, Kuno T, Nakai H, Yamadori T, et al. Decreased serotonin S2 and increased dopamine D2 receptors in chronic schizophrenics. Biol Psychiatry. 1986;21(14):1407-14.

70.Kos MZ, Duan J, Sanders AR, Blondell L, Drigalenko EI, Carless MA, et al. Dopamine perturbation of gene co-expression networks reveals differential response in schizophrenia for translational machinery. Transl Psychiatry. 2018;8(1):278.

71.Consortium NaPASoPG. Psychiatric genome-wide association study analyses implicate neuronal, immune and histone pathways. Nat Neurosci. 2015;18(2):199-209.

72.Purcell SM, Moran JL, Fromer M, Ruderfer D, Solovieff N, Roussos P, et al. A polygenic burden of rare disruptive mutations in schizophrenia. Nature. 2014;506(7487):185-90.

73.Fromer M, Pocklington AJ, Kavanagh DH, Williams HJ, Dwyer S, Gormley P, et al. De novo mutations in schizophrenia implicate synaptic networks. Nature. 2014;506(7487):179-84.

74.Rapoport JL, Giedd JN, Blumenthal J, Hamburger S, Jeffries N, Fernandez T, et al. Progressive cortical change during adolescence in childhood-onset schizophrenia. A longitudinal magnetic resonance imaging study. Arch Gen Psychiatry. 1999;56(7):649-54.

75.Goghari VM, Rehm K, Carter CS, MacDonald AW 3rd. Regionally specific cortical thinning and gray matter abnormalities in the healthy relatives of schizophrenia patients. Cereb Cortex. 2007;17(2):415-24.

76.Lewis DA, Gonzalez-Burgos G. Neuroplasticity of neocortical circuits in schizophrenia. Neuropsychopharmacology. 2008;33(1):141-65.

77.Harris KM. Structure, development, and plasticity of dendritic spines. Curr Opin Neurobiol. 1999;9(3):343-8.

78.Prasad KM, Goradia D, Eack S, Rajagopalan M, Nutche J, Magge T, et al. Cortical surface characteristics among offspring of schizophrenia subjects. Schizophr Res. 2010;116(2-3):143-51.

79.Harms MP, Wang L, Campanella C, Aldridge K, Moffitt AJ, Kuelper J, et al. Structural abnormalities in gyri of the prefrontal cortex in individuals with schizophrenia and their unaffected siblings. Br J Psychiatry. 2010;196(2):150-7.

80.Thyme SB, Pieper LM, Li EH, Pandey S, Wang Y, Morris NS, et al. Phenotypic Landscape of Schizophrenia-Associated Genes Defines Candidates and Their Shared Functions. Cell. 2019;177(2):478-91.e20.

81.Andreassen OA, Thompson WK, Dale AM. Boosting the power of schizophrenia genetics by leveraging new statistical tools. Schizophr Bull. 2014;40(1):13-7.

82.McCarthy SE, Gillis J, Kramer M, Lihm J, Yoon S, Berstein Y, et al. De novo mutations in schizophrenia implicate chromatin remodeling and support a genetic overlap with autism and intellectual disability. Mol Psychiatry. 2014;19(6):652-8.

83.Curtis D. Pathway analysis of whole exome sequence data provides further support for the involvement of histone modification in the aetiology of schizophrenia. Psychiatr Genet. 2016;26(5):223-7.

84.Takata A, Xu B, Ionita-Laza I, Roos JL, Gogos JA, Karayiorgou M. Loss-of-function variants in schizophrenia risk and SETD1A as a candidate susceptibility gene. Neuron. 2014;82(4):773-80.

85.Singh T, Kurki MI, Curtis D, Purcell SM, Crooks L, McRae J, et al. Rare loss-of-function variants in SETD1A are associated with schizophrenia and developmental disorders. Nat Neurosci. 2016;19(4):571-7.

86.Li Y, Jiao J. Histone chaperone HIRA regulates neural progenitor cell proliferation and neurogenesis via beta-catenin. J Cell Biol. 2017;216(7):1975-92.

87.Franke M, Ibrahim DM, Andrey G, Schwarzer W, Heinrich V, Schopflin R, et al. Formation of new chromatin domains determines pathogenicity of genomic duplications. Nature. 2016;538(7624):265-9.

88.Redin C, Brand H, Collins RL, Kammin T, Mitchell E, Hodge JC, et al. The genomic landscape of balanced cytogenetic abnormalities associated with human congenital anomalies. Nat Genet. 2017;49(1):36-45.

89.Zeitz MJ, Lerner PP, Ay F, Van Nostrand E, Heidmann JD, Noble WS, et al. Implications of COMT long-range interactions on the phenotypic variability of 22q11.2 deletion syndrome. Nucleus. 2013;4(6):487-93.

90.Moy M, Duan J, Drigalenko E, Freda J, MGS., Göring HHH, et al. Transcriptome signature of schizophrenia-associated rare copy number variants (CNVs) in lymphoblastoid cell lines (LCLs). Abstract presented at ASHG 2014. American Society of Human Genetics 64th Annual Meeting; 2014 Oct 18–22; San Diego, CA, USA.

91.Torshizi AD, Armoskus C, Zhang H, Forrest MP, Zhang S, Souaiaia T, et al. Deconvolution of transcriptional networks identifies TCF4 as a master regulator in schizophrenia. Sci Adv. 2019;5(9):eaau4139. doi: 10.1126/sciadv.aau4139

92.Forrest MP, Hill MJ, Kavanagh DH, Tansey KE, Waite AJ, Blake DJ. The Psychiatric Risk Gene Transcription Factor 4 (TCF4) Regulates Neurodevelopmental Pathways Associated With Schizophrenia, Autism, and Intellectual Disability. Schizophr Bull. 2018;44(5):1100-10. doi: 10.1093/schbul/sbx164

93.Lopez-Atalaya JP, Ito S, Valor LM, Benito E, Barco A. Genomic targets, and histone acetylation and gene expression profiling of neural HDAC inhibition. Nucleic Acids Res. 2013;41(17):8072-84.

94.Parsa CF, Robert MP. Thromboembolism and congenital malformations: from Duane syndrome to thalidomide embryopathy. JAMA Ophthalmol. 2013;131(4):439-47.

95.Susser E, St Clair D, He L. Latent effects of prenatal malnutrition on adult health: the example of schizophrenia. Ann N Y Acad Sci. 2008;1136:185-92.

96.Kohli RM, Zhang Y. TET enzymes, TDG and the dynamics of DNA demethylation. Nature. 2013;502(7472):472-9.

97.Aberg KA, McClay JL, Nerella S, Clark S, Kumar G, Chen W, et al. Methylome-wide association study of schizophrenia: identifying blood biomarker signatures of environmental insults. JAMA Psychiatry. 2014;71(3):255-64.

98.McClay JL, Shabalin AA, Dozmorov MG, Adkins DE, Kumar G, Nerella S, et al. High density methylation QTL analysis in human blood via next-generation sequencing of the methylated genomic DNA fraction. Genome Biol. 2015;16:291.

99.Jaffe AE, Gao Y, Deep-Soboslay A, Tao R, Hyde TM, Weinberger DR, et al. Mapping DNA methylation across development, genotype and schizophrenia in the human frontal cortex. Nat Neurosci. 2016;19(1):40-7.

100.Hannon E, Spiers H, Viana J, Pidsley R, Burrage J, Murphy TM, et al. Methylation QTLs in the developing brain and their enrichment in schizophrenia risk loci. Nat Neurosci. 2016;19(1):48-54.

101.Akbarian S, Ruehl MG, Bliven E, Luiz LA, Peranelli AC, Baker SP, et al. Chromatin alterations associated with down-regulated metabolic gene expression in the prefrontal cortex of subjects with schizophrenia. Arch Gen Psychiatry. 2005;62(8):829-40.

102.Chase KA, Gavin DP, Guidotti A, Sharma RP. Histone methylation at H3K9: evidence for a restrictive epigenome in schizophrenia. Schizophr Res. 2013;149(1-3):15-20.

103.Kano S, Colantuoni C, Han F, Zhou Z, Yuan Q, Wilson A, et al. Genome-wide profiling of multiple histone methylations in olfactory cells: further implications for cellular susceptibility to oxidative stress in schizophrenia. Mol Psychiatry. 2013;18(7):740-2.

104.Mukai J, Cannavo E, Crabtree GW, Sun Z, Diamantopoulou A, Thakur P, et al. Recapitulation and reversal of schizophrenia-related phenotypes in Setd1a-deficient mice. BioRxiv
[Preprint]. 2019. doi: 10.1101/529701

105.Gavin DP, Kartan S, Chase K, Grayson DR, Sharma RP. Reduced baseline acetylated histone 3 levels, and a blunted response to HDAC inhibition in lymphocyte cultures from schizophrenia subjects. Schizophr Res. 2008;103(1-3):330-2.

106.Tang B, Dean B, Thomas EA. Disease- and age-related changes in histone acetylation at gene promoters in psychiatric disorders. Transl Psychiatry. 2011;1:e64. doi: 10.1038/tp.2011.61

107.Sun W, Poschmann J, Cruz-Herrera Del Rosario R, Parikshak NN, Hajan HS, Kumar V, et al. Histone Acetylome-wide Association Study of Autism Spectrum Disorder. Cell. 2016;167(5):1385-97.e11.

108.Furey TS, Sethupathy P. Genetics. Genetics driving epigenetics. Science. 2013;342(6159):705-6.

109.Stower H. Gene regulation: from genetic variation to phenotype via chromatin. Nat Rev Genet. 2013;14(12):824.

110.Kilpinen H, Waszak SM, Gschwind AR, Raghav SK, Witwicki RM, Orioli A, et al. Coordinated effects of sequence variation on DNA binding, chromatin structure, and transcription. Science. 2013;342(6159):744-7.

111.Kasowski M, Kyriazopoulou-Panagiotopoulou S, Grubert F, Zaugg JB, Kundaje A, Liu Y, et al. Extensive variation in chromatin states across humans. Science. 2013;342(6159):750-2.

112.Degner JF, Pai AA, Pique-Regi R, Veyrieras JB, Gaffney DJ, Pickrell JK, et al. DNase I sensitivity QTLs are a major determinant of human expression variation. Nature. 2012;482(7385):390-4.

113.Fullard JF, Giambartolomei C, Hauberg ME, Xu K, Voloudakis G, Shao Z, et al. Open chromatin profiling of human postmortem brain infers functional roles for non-coding schizophrenia loci. Hum Mol Genet. 2017;26(10):1942-51.

114.Forrest MP, Zhang H, Moy W, McGowan H, Leites C, Dionisio LE, et al. Open Chromatin Profiling in hiPSC-Derived Neurons Prioritizes Functional Noncoding Psychiatric Risk Variants and Highlights Neurodevelopmental Loci. Cell Stem Cell. 2017;21(3):305-18.e8.

115.Dekker J, Marti-Renom MA, Mirny LA. Exploring the three-dimensional organization of genomes: interpreting chromatin interaction data. Nat Rev Genet. 2013;14(6):390-403.

116.Won H, de la Torre-Ubieta L, Stein JL, Parikshak NN, Huang J, Opland CK, et al. Chromosome conformation elucidates regulatory relationships in developing human brain. Nature. 2016;538(7626):523-7.

117.Alexander Arguello P, Addington A, Borja S, Brady L, Dutka T, Gitik M, et al. From genetics to biology: advancing mental health research in the Genomics ERA. Mol Psychiatry. 2019. doi: 10.1038/s41380-019-0445-x

118.Panchision DM. Concise Review: Progress and Challenges in Using Human Stem Cells for Biological and Therapeutics Discovery: Neuropsychiatric Disorders. Stem Cells. 2016;34(3):523-36.

119.Wen Z, Christian KM, Song H, Ming GL. Modeling psychiatric disorders with patient-derived iPSCs. Curr Opin Neurobiol. 2016;36:118-27.

120.Pasca AM, Sloan SA, Clarke LE, Tian Y, Makinson CD, Huber N, et al. Functional cortical neurons and astrocytes from human pluripotent stem cells in 3D culture. Nat Methods. 2015;12(7):671-8.

121.Rigamonti A, Repetti GG, Sun C, Price FD, Reny DC, Rapino F, et al. Large-Scale Production of Mature Neurons from Human Pluripotent Stem Cells in a Three-Dimensional Suspension Culture System. Stem Cell Rep. 2016;6(6):993-1008.

122.Brennand KJ, Simone A, Jou J, Gelboin-Burkhart C, Tran N, Sangar S, et al. Modelling schizophrenia using human induced pluripotent stem cells. Nature. 2011;473(7346):221-5.

123.Vierbuchen T, Ostermeier A, Pang ZP, Kokubu Y, Sudhof TC, Wernig M. Direct conversion of fibroblasts to functional neurons by defined factors. Nature. 2010;463(7284):1035-41.

124.Zhang Y, Pak C, Han Y, Ahlenius H, Zhang Z, Chanda S, et al. Rapid single-step induction of functional neurons from human pluripotent stem cells. Neuron. 2013;78(5):785-98.

125.Lipska BK, Deep-Soboslay A, Weickert CS, Hyde TM, Martin CE, Herman MM, et al. Critical factors in gene expression in postmortem human brain: Focus on studies in schizophrenia. Biol Psychiatry. 2006;60(6):650-8.

126.Duan J. Path from schizophrenia genomics to biology: gene regulation and perturbation in neurons derived from induced pluripotent stem cells and genome editing. Neurosci Bull. 2015;31(1):113-27.

127.Kriks S, Shim JW, Piao J, Ganat YM, Wakeman DR, Xie Z, et al. Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson’s disease. Nature. 2011;480(7378):547-51.

128.Shi Y, Kirwan P, Smith J, Robinson HP, Livesey FJ. Human cerebral cortex development from pluripotent stem cells to functional excitatory synapses. Nat Neurosci. 2012;15(3):477-86, S1.

129.Liu Y, Liu H, Sauvey C, Yao L, Zarnowska ED, Zhang SC. Directed differentiation of forebrain GABA interneurons from human pluripotent stem cells. Nat Protoc. 2013;8(9):1670-9.

130.Maroof AM, Keros S, Tyson JA, Ying SW, Ganat YM, Merkle FT, et al. Directed differentiation and functional maturation of cortical interneurons from human embryonic stem cells. Cell Stem Cell. 2013;12(5):559-72.

131.Nicholas CR, Chen J, Tang Y, Southwell DG, Chalmers N, Vogt D, et al. Functional maturation of hPSC-derived forebrain interneurons requires an extended timeline and mimics human neural development. Cell Stem Cell. 2013;12(5):573-86.

132.Muffat J, Li Y, Yuan B, Mitalipova M, Omer A, Corcoran S, et al. Efficient derivation of microglia-like cells from human pluripotent stem cells. Nat Med. 2016;22(11):1358-67.

133.Yang N, Chanda S, Marro S, Ng YH, Janas JA, Haag D, et al. Generation of pure GABAergic neurons by transcription factor programming. Nat Methods. 2017;14(6):621-8.

134.Arlotta P. Organoids required! A new path to understanding human brain development and disease. Nat Methods. 2018;15(1):27-9.

135.Pasca SP. Assembling human brain organoids. Science. 2019;363(6423):126-7.

136.Qian X, Song H, Ming GL. Brain organoids: advances, applications and challenges. Development. 2019;146(8):dev166074. doi: 10.1242/dev.166074

137.Pasca SP. The rise of three-dimensional human brain cultures. Nature. 2018;553(7689):437-45.

138.Amin ND, Pasca SP. Building Models of Brain Disorders with Three-Dimensional Organoids. Neuron. 2018;100(2):389-405.

139.Wen Z, Nguyen HN, Guo Z, Lalli MA, Wang X, Su Y, et al. Synaptic dysregulation in a human iPS cell model of mental disorders. Nature. 2014;515(7527):414-8.

140.Yoon KJ, Nguyen HN, Ursini G, Zhang F, Kim NS, Wen Z, et al. Modeling a genetic risk for schizophrenia in iPSCs and mice reveals neural stem cell deficits associated with adherens junctions and polarity. Cell Stem Cell. 2014;15(1):79-91.

141.Das DK, Tapias V, D’Aiuto L, Chowdari KV, Francis L, Zhi Y, et al. Genetic and morphological features of human iPSC-derived neurons with chromosome 15q11.2 (BP1-BP2) deletions. Mol Neuropsychiatry. 2015;1(2):116-23.

142.Zhao D, Lin M, Chen J, Pedrosa E, Hrabovsky A, Fourcade HM, et al. MicroRNA Profiling of Neurons Generated Using Induced Pluripotent Stem Cells Derived from Patients with Schizophrenia and Schizoaffective Disorder, and 22q11.2 Del. PLoS One. 2015;10(7):e0132387.

143.Toyoshima M, Akamatsu W, Okada Y, Ohnishi T, Balan S, Hisano Y, et al. Analysis of induced pluripotent stem cells carrying 22q11.2 deletion. Transl Psychiatry. 2016;6(11):e934.

144.Jiang X, Detera-Wadleigh SD, Akula N, Mallon BS, Hou L, Xiao T, et al. Sodium valproate rescues expression of TRANK1 in iPSC-derived neural cells that carry a genetic variant associated with serious mental illness. Mol Psychiatry. 2019;24(4):613-24.

145.Soldner F, Laganiere J, Cheng AW, Hockemeyer D, Gao Q, Alagappan R, et al. Generation of isogenic pluripotent stem cells differing exclusively at two early onset Parkinson point mutations. Cell. 2011;146(2):318-31.

146.Hockemeyer D, Wang H, Kiani S, Lai CS, Gao Q, Cassady JP, et al. Genetic engineering of human pluripotent cells using TALE nucleases. Nat Biotechnol. 2011;29(8):731-4.

147.Sanjana NE, Cong L, Zhou Y, Cunniff MM, Feng G, Zhang F. A transcription activator-like effector toolbox for genome engineering. Nat Protoc. 2012;7(1):171-92.

148.Ding Q, Lee YK, Schaefer EA, Peters DT, Veres A, Kim K, et al. A TALEN Genome-Editing System for Generating Human Stem Cell-Based Disease Models. Cell Stem Cell. 2013;12(2):238-51. doi: 10.1016/j.stem.2012.11.011

149.Reyon D, Tsai SQ, Khayter C, Foden JA, Sander JD, Joung JK. FLASH assembly of TALENs for high-throughput genome editing. Nat Biotechnol. 2012;30(5):460-5.

150.Joung JK, Sander JD. TALENs: a widely applicable technology for targeted genome editing. Nat Rev Mol Cell Biol. 2012;14(1):49-55.

151.Bedell VM, Wang Y, Campbell JM, Poshusta TL, Starker CG, Krug RG, 2nd, et al. In vivo genome editing using a high-efficiency TALEN system. Nature. 2012;491(7422):114-8.

152.Schmid-Burgk JL, Schmidt T, Kaiser V, Honing K, Hornung V. A ligation-independent cloning technique for high-throughput assembly of transcription activator-like effector genes. Na

引用本文

Jubao Duan*,Alan R. Sanders,Pablo V. Gejman. From Schizophrenia Genetics to Disease Biology: Harnessing New Concepts and Technologies, Journal of Psychiatry and Brain Science. 2019; 4; (5). https://doi.org/10.20900/jpbs.20190014.

文献评论

相关学者

相关机构